FDA adds new safety information to statin drugs

(AP) -- Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, a widely prescribed group of cholesterol-lowering medications.

The Food and Drug Administration announced several labeling changes to medicines like Lipitor, Crestor and Zocor.

Labeling on all such drugs will warn of memory loss and confusion reported among certain patients taking statins. The problems were generally not serious and went away after patients stopped taking the drugs, according to the FDA.

The updated labels will also mention elevated levels of blood sugar reported in some patients taking statins.

Statins are mainly prescribed to prevent heart attacks in people with and work by dramatically lowering LDL or "." They were the third best-selling drug class in the U.S. for 2010.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA confirms benefits of Crestor in more patients

Dec 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments